# EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19

> **NCT05059106** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Federal University of Espirito Santo** · enrollment: 29637 (estimated)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** Half dose of ChAdOx1 nCoV-19 (AZD1222)
- **BIOLOGICAL:** Standard dose of ChAdOx1 nCoV-19 (AZD1222)

## Key facts

- **NCT ID:** NCT05059106
- **Lead sponsor:** Federal University of Espirito Santo
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-01
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-10-30
- **Target enrollment:** 29637 (ESTIMATED)
- **Last updated:** 2021-09-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05059106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05059106, "EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05059106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*